Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05332002 · ClinicalTrials.gov registry record · Phase 2
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
A Phase 2 study of Gastrointestinal Cancer, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 6
- Study locations
NCT05332002: Recruiting Phase 2 study of Gastrointestinal Cancer, sponsored by Rutgers, The State University of New Jersey.
NCT05332002 is a Phase 2 study of Gastrointestinal Cancer that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 38 participants, below the 229-participant average among 49 other Gastrointestinal Cancer trials with a reported enrollment target (83% lower). The trial reports 6 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05332002, a Phase 2 study of Gastrointestinal Cancer, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 6
- Study locations
Study Summary
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.
Primary Outcome
To determine the clinical efficacy of treatment regimen in terms of objective response rate.
Conditions Studied
Interventions
- DRUG Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
Study Locations (6)
New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital - Hamilton
- RWJBarnabas Health - Monmouth Medical Center Southern Campus - Lakewood
- RWJBarnabas Health - Monmouth Medical Center - Long Branch
- Rutgers Cancer Institute of New Jersey - New Brunswick
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset - New Brunswick
- RWJBarnabas Health - Newark Beth Israel Medical Center - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-07-13 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 2 |
What NCT05332002 shows while recruiting
NCT05332002 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 229-participant average among 49 other Gastrointestinal Cancer trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Gastrointestinal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI) is the first listed.
NCT05332002 lists 6 locations in 1 state (New Jersey).
Frequently Asked Questions
What is clinical trial NCT05332002 about?
NCT05332002 is a clinical study titled "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)". The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to ch...
What is the current status of trial NCT05332002?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2022-07-13. Estimated completion is 2026-08-01.
What conditions does trial NCT05332002 study?
This clinical trial studies the following conditions: Gastrointestinal Cancer.
What interventions are being tested in trial NCT05332002?
The interventions under investigation include: Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI) (DRUG).
Who is sponsoring clinical trial NCT05332002?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05332002 being conducted?
This trial has 6 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05332002's enrollment target sits among peer trials
38 40th of 49 higher than 10 of 49 other Gastrointestinal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastrointestinal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
RECRUITING · Phase 2
-
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
RECRUITING · Phase 2
-
Avatrombopag vs. Placebo for CIT in GI Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
ACTIVE NOT RECRUITING · Phase 2
-
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI